Helsinn Healthcare S.A. et al. v. Qilu Pharmaceutical Co., Ltd. et al.

I'll research this case thoroughly before drafting the overview.

Let me dig deeper into the specific patents, the docket, and the case history.

Let me examine the complaint analysis and the specific docket record.

Case Overview — Helsinn Healthcare S.A. et al. v. Qilu Pharmaceutical Co., Ltd. et al., No. 15-cv-08132 (D.N.J.)

Parties. Both plaintiffs are operating life-sciences companies, not NPEs/PAEs. Helsinn Healthcare S.A. is a privately held Swiss oncology-support company (HQ Lugano/Pazzallo, founded 1976) that holds NDA No. 021372 for ALOXI® (palonosetron hydrochloride injection) and markets it in the U.S. through its collaborator Eisai (which acquired U.S./Canadian Aloxi commercial rights via MGI Pharma). Roche Palo Alto LLC — the Palo Alto Roche entity that succeeded to the Syntex/Roche palonosetron work — is a co-plaintiff as co-owner of certain formulation patents (the Palo Alto inventors Miksztal, Malefyt and Lee assigned to Roche; Roche is a named assignee on, e.g., the '724 and '905 patents), not a marketer of the drug. Per filings in the related D.N.J. cases, Helsinn acquired the right to develop palonosetron from Roche in 1998. Defendants are Qilu Pharmaceutical Co., Ltd. (the Chinese generic manufacturer) and Qilu Pharma, Inc., its U.S. affiliate/agent, which maintains a registered U.S. presence (Malvern, PA on the ANDA; a Princeton, NJ address in later matters) and has repeatedly consented to New Jersey jurisdiction (cited in later complaints filed by Janssen, Boehringer Ingelheim, Eli Lilly and Heron, e.g., https://paragraphfour.com/wp-content/uploads/2018/01/njdc24cv7094A.pdf).

Accused product and patents. The accused act is Qilu's submission of ANDA No. 205648 for generic palonosetron hydrochloride injection, 0.25 mg (base)/5 mL and 0.075 mg (base)/1.5 mL single-dose vials — a generic of Aloxi — with a Paragraph IV certification; infringement is pleaded under 35 U.S.C. § 271(e)(2)(A). FDA records the ANDA as received for review April 9, 2014, tentatively approved April 26, 2018, and finally approved September 19, 2018 (after the shared 180-day exclusivity) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/205648Orig1s000TAltr.pdf; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205648). The asserted patents are all members of the same palonosetron liquid-formulation family (priority to provisional 60/444,351, filed Jan. 30, 2003, via PCT/EP2004/000888), all with Orange Book expirations of July 30, 2024 (with pediatric exclusivity):

• '724 (7,947,724) — "Liquid pharmaceutical formulations of palonosetron": a stable, sterile, isotonic aqueous IV solution of palonosetron (~0.03–0.2 mg/mL) with mannitol, EDTA and citrate buffer, stable ≥24 months at room temperature.
• '980 (9,066,980) — same family: single-use, unit-dose stable liquid palonosetron formulations.
• '942 (9,173,942) — same family: stable aqueous IV formulation with palonosetron HCl, a mannitol concentration range and a chelating agent, pH 4.0–6.0.
• '905 (9,125,905) — same family: sterile aqueous IV solution containing 0.25 mg palonosetron at 0.03–0.2 mg/mL, plus method-of-manufacture and finished-container claims (https://www.drugpatentwatch.com/p/patent/9125905).

Procedural posture and venue. Helsinn and Roche filed in the U.S. District Court for the District of New Jersey on Nov. 17, 2015 — reported in databases variously as 2:15-cv-08132 (Newark vicinage) and 3:15-cv-08132 — and the case was subsequently dismissed/closed; FDA's tentative-approval letter confirms the agency was notified that the action "was dismissed." New Jersey was a natural forum: Qilu Pharma maintained a registered New Jersey/U.S. presence, the Aloxi ANDA litigation was heavily concentrated in D.N.J., and the Federal Circuit's Acorda v. Mylan line (applied in Helsinn v. Hospira) validated New Jersey specific jurisdiction over ANDA filers based on their anticipated distribution networks. I could not confirm the assigned judge, the exact dismissal date, or the operative dismissal docket entry from the sources available; those points should be verified against PACER/RECAP.

Why it is notable — and two sourcing caveats. This case is one docket in Helsinn's unusually large Aloxi enforcement campaign; a Sagent filing states Helsinn sued at least fifteen other ANDA sponsors in addition to Teva, Dr. Reddy's, Sandoz and Sagent (https://storage.courtlistener.com/recap/gov.uscourts.njd.[351305](/patent/351305)/gov.uscourts.njd.351305.53.0.pdf). Its significance flows from the parallel Helsinn v. Teva litigation, in which the Federal Circuit (855 F.3d 1356 (Fed. Cir. 2017)) affirmed on-sale-bar invalidity of the '724, '725, '424 and '219 patents, and the Supreme Court affirmed (139 S. Ct. 628 (2019)) — the leading authority that a "sale" under the pre-AIA § 102(b) bar does not require public disclosure of the invention's details. That ruling invalidated the '724 patent, the lead patent here, and D.N.J. later denied Helsinn a preliminary injunction against Teva's generic. The family was also heavily challenged at the PTAB — e.g., Dr. Reddy's PGR2016-00008 on the '942 patent (instituted Aug. 17, 2016) and an IPR on the '094 patent — so this case sits at the intersection of Hatch-Waxman ANDA filings, on-sale-bar/§ 102 jurisprudence, and post-grant PTAB challenges; the generics (Teva at-risk March 23, 2018, then Dr. Reddy's and Sandoz) ultimately launched, with Qilu's product approved in September 2018. Two caveats: (1) the fourth asserted patent is reported inconsistently — this case's metadata lists the '905 patent, while FDA's ANDA 205648 tentative-approval letter states litigation was brought on the '724, '094, '980 and '942 patents in "Civil Action No. 15-8132." Both agree on '724, '980 and '942; I could not resolve whether the complaint pleaded '905, '094, or both (the '905 issued Sept. 8, 2015 and the '942 on Nov. 3, 2015, just before the Nov. 17, 2015 complaint, and a docket or complaint pull would settle it). (2) Helsinn's broader 2022–2025 filings against Qilu concern different products and patents (netupitant/palonosetron and fosnetupitant/palonosetron Akynzeo NDAs, and Heron's APONVIE/CINVANTI in D. Del.), not this case.

I'll research the docket and related proceedings before drafting.

Let me pull the actual docket and complaint analysis.

Key Legal Developments and Outcome — Helsinn Healthcare S.A. v. Qilu Pharmaceutical Co., Ltd., No. 15-cv-08132 (D.N.J.)

Bottom line: this was a "protective" Hatch-Waxman case. It was filed to preserve the 30-month stay and the § 271(e)(2) cause of action, generated essentially no substantive motion practice in its own right, and ended by settlement and dismissal rather than by any merits ruling. The validity and infringement law that governed it was made in the parallel Helsinn v. Teva / Helsinn v. Dr. Reddy's actions. I could not pull the PACER/RECAP docket itself (search budget exhausted); the chronology below is reconstructed from the FDA approval letter, the complaint-analysis record, the E.D. Pa. companion docket, and Helsinn's later D.N.J. filings, with gaps flagged.

I. Filing and initial pleadings

• 2014-04-09 — FDA receives ANDA No. 205648 (Qilu; palonosetron HCl 0.25 mg/5 mL and 0.075 mg/1.5 mL single-dose vials). This is the operative infringing act under § 271(e)(2)(A).
• 2015-09-08 — '905 patent issues; 2015-11-03 — '942 patent issues. The '942 patent issued two weeks before the complaint, which is why the complaint pleads it in a distinct count (¶¶47–51) on a "continuing to seek approval after issuance" theory rather than on the original notice letter.
• 2015-11-17 — Helsinn and Roche Palo Alto file the D.N.J. complaint within the 45-day § 505(j)(5)(B)(iii) window. The pleaded counts, as captured in the complaint analysis (https://ai-lab-cl-prod.azurewebsites.net/case/dct/njd/2:15-cv-08132/doc/analysis/1), are: '724 (Count/¶¶25, 33), '980 (¶¶39–41), '942 (¶¶47–51), preceded at ¶13 by the ANDA/product description. Notably, the analysis identifies only these three patents, and pleads infringement generically under § 271(e)(2)(A) with no claim chart or element-by-element factual allegations — a bare-bones "statutory" complaint typical of the 2015 Aloxi wave.
• 2015-12-01 — A second, parallel complaint is filed in E.D. Pa.: Helsinn Healthcare S.A. et al. v. Qilu Pharmaceutical Co., Ltd. et al., No. 2:15-cv-06392 (E.D. Pa.), assigned to Judge Cynthia M. Rufe (https://dockets.justia.com/docket/pennsylvania/paedce/2:2015cv06392/[511727](/patent/511727)). This is almost certainly a protective/duplicative filing keyed to Qilu Pharma, Inc.'s U.S. agent address in Malvern, PA (the address on the ANDA and on the FDA correspondence), filed to hedge against a personal-jurisdiction challenge in New Jersey. The Justia docket mislabels the cause as "35 U.S.C. § 145," which is a docketing artifact — the parties and patents are identical to the D.N.J. case. This companion filing is not reflected in the case metadata and should be flagged; it also means the "outcome" has two dismissal events to verify.
• Answer/counterclaims: I found no evidence of an answered complaint, counterclaims of invalidity/non-infringement, or any Rule 12 motion in this docket. Given the disposition (settlement before any substantive motion), the case most likely never progressed past waiver-of-service/extension practice. Treat the absence of an answer as unverified but consistent with the record rather than established.

II. Pre-trial motions of substance

None identified in this docket. No motion to dismiss, transfer, stay-pending-IPR, or summary-judgment motion is attributable to No. 15-8132 in any source I located. Qilu's parent-company/subsidiary structure (Qilu Pharmaceutical Co., Ltd. and Qilu Pharma, Inc.) would have supported a Rule 12(b)(2) motion, but the D.N.J. record in the sister Aloxi cases had already resolved that question adversely to generics — Helsinn Healthcare S.A. v. Hospira, Inc., No. 15-2077 (D.N.J.), slip op. at *6–12 (D.I. 86), applying Acorda v. Mylan to hold that an ANDA filer's distribution network and its U.S. affiliate's New Jersey registration establish specific jurisdiction (https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2015cv02077/[316695](/patent/316695)/86/0.pdf). The Hospira court also sustained Helsinn's § 271(b) inducement theory against a non-ANDA-holder affiliate — the same theory Helsinn would have used against Qilu Pharma, Inc. That precedent likely suppressed motion practice here.

No Markman, no discovery milestones of record, no trial, no verdict, no JMOL/new-trial/fee motion. The case did not reach claim construction.

III. Disposition — settlement and dismissal

• Helsinn's own litigation narrative confirms the disposition: in Helsinn v. Sagent (D.N.J. No. 17-? , RECAP 351305), Helsinn stated that "only the following five other ANDA sponsors have tentative approval at present and have settled their cases with Helsinn: Aurobindo Pharma Ltd.; Akorn, Inc.; Qilu Pharmaceutical Co., Somerset Therapeutics, LLC, and Fresenius Kabi USA, LLC" (D.I. 71 at 10–11, https://storage.courtlistener.com/recap/gov.uscourts.njd.351305/gov.uscourts.njd.351305.71.0.pdf). Unlike the Sandoz and Dr. Reddy's settlements — which produced consent judgments with express injunctions and launch dates of "September 30, 2018 or earlier under certain circumstances" (id., quoting the Sandoz Order in No. 2:11-cv-03962, D.I. 247, and the Dr. Reddy's Stipulation of Dismissal entered 2015-10-16, D.I. 355) — I found no reported consent judgment or injunction against Qilu. The Qilu settlement appears to have been a license/settlement with a stipulated dismissal only.
• 2018-04-26 — FDA tentatively approves ANDA 205648. The letter is the best single record of the case's end state: it recites that litigation was brought on the '724, '094, '980 and '942 patents in "Civil Action No. 15-8132" and that FDA "was notified that this case was dismissed" (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/205648Orig1s000TAltr.pdf).
• 2018-09-19 — Qilu receives final approval, the first day of eligibility after the shared 180-day exclusivity expired (Dr. Reddy's/Sandoz at-risk launches in March/April 2018 triggered it). Final approval on the exclusivity-expiry date, rather than earlier, is consistent with the settlement's launch terms but does not by itself prove them.

IV. Parallel PTAB proceedings and their effect

• PGR2016-00008 (Dr. Reddy's) on the '942 patent, instituted 2016-08-17, is the post-grant challenge most directly aimed at a patent asserted here; there was also an IPR on the '094 patent. These are summarized in the case overview and I did not locate anything in this record tying Qilu to a petition of its own.
• The practical effect on No. 15-8132 was indirect: the '942 and '094 validity fights were being litigated elsewhere, and any stay would have been sought against that backdrop. I could not verify whether Qilu filed or joined any IPR/PGR on the '724, '905, '980, '942 or '094 patents — this is the single largest unresolved item on the PTAB side.

V. The decisive external development: the '724 patent fell

The lead asserted patent was invalidated outside this case:

Because the '724 patent — the backbone of every Aloxi ANDA case — was invalid as of May 2017, this docket's settlement value collapsed to the residual '094/'980/'942 claims and the exclusivity calendar, which is exactly the posture in which the other five tentative-approval sponsors (including Qilu) settled.

VI. Caveats and open items

1. The fourth-patent discrepancy persists and now has a third data point. FDA says '724, '094, '980, '942; the complaint analysis documents counts for '724, '980, '942 only; the case metadata says '905. The most likely reconciliation is that the complaint asserted '724, '980, '942 (per the analysis), the '094 was added by amendment or was the fourth patent in the FDA notification, and the metadata's '905 is an error — but this is inference, not verification. A complaint pull (D.I. 1) settles it.
2. Dismissal date and docket entry unverified, as is any Fed. R. Civ. P. 41(a) stipulation, and whether dismissal of No. 15-8132 was matched by a dismissal of E.D. Pa. No. 2:15-cv-06392.
3. Assigned D.N.J. judge unverified (the E.D. Pa. judge is confirmed as Rufe).

I'll research the docket and counsel appearances for this case.

Initial results identify the judge and likely counsel. Let me pull the actual docket and the complaint.

Strong leads on the counsel team. Now let me confirm the specific Qilu docket appearances.

Counsel of Record — Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC

Research note / correction to earlier sections. The docket caption resolves one open item from the case overview: the number appears in later Helsinn pleadings as Civil Action No. 15‑8132 (MLC)(DEA), i.e., District Judge Mary L. Cooper with Magistrate Judge Douglas E. Arpert — the same MLC/DEA pairing that handled the consolidated Aloxi ANDA litigation (Hospira 15‑2077, Fresenius Kabi 15‑7378). See Helsinn pleading citing "Helsinn Healthcare S.A., et al. v. Qilu Pharmaceuticals Co., Ltd., et al., Civil Action No. 15-8132 (MLC)(DEA) (D.N.J.)" (https://storage.courtlistener.com/recap/gov.uscourts.njd.[351307](/patent/351307)/gov.uscourts.njd.351307.1.0_1.pdf) and Qilu's own later admissions cataloguing the action (https://paragraphfour.com/wp-content/uploads/2018/01/njdc24cv7094A.pdf).

Important caveat on sourcing. This docket is closed and the Qilu papers are only thinly indexed on free services (CourtListener/RECAP has no fully downloadable 15‑8132 docket sheet that I could retrieve; Docket Alarm's page for the case is not publicly crawlable). The roster below therefore blends (a) a direct, docket-linked hit for this case number and (b) the signature blocks of contemporaneous Helsinn/Roche Aloxi pleadings in the same campaign, which I flag as to confidence. I have not invented any name; where I could not tie an attorney to this docket entry I say so.

Tier 1 — Confirmed appearance on this docket

Tier 2 — Same-firm team that signed Helsinn/Roche Aloxi pleadings in the identical window (very likely on this docket; no direct entry retrieved)

Tier 3 — Separate plaintiff-side counsel appearing on Helsinn/Roche Aloxi pleadings

What I could not verify

• No in-house counsel for Helsinn or Roche appears in any public Aloxi filing I reviewed; Helsinn Therapeutics U.S. Inc. legal personnel do not appear as counsel of record. None should be assumed.
• No sealed appearance or pro hac vice order specific to 15‑8132 was retrievable, so the exact set of Paul Hastings attorneys formally admitted in this docket (as opposed to signing the complaint) is unconfirmed. The Saul Ewing local-counsel appearance and the Paul Hastings signature block are the two anchors.
• A full PACER docket pull for 3:15-cv-08132 (MLC)(DEA) (or the 2:15‑cv‑08132 Newark-vicinage variant) would settle: the precise appearance entries, whether Loeb & Loeb filed a separate appearance for Roche, and the dismissal entry date — all three remain open items flagged in the earlier case-overview section.
• Do not confuse this roster with Helsinn's 2022–2025 Qilu matters (Akynze

I'll research the docket and identify defense counsel.